Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
暂无分享,去创建一个
[1] G. Koning,et al. A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[2] Steven H. Liang,et al. Discovery of [11C]PF-367 for neuroimaging of glycogen synthase kinase 3 , 2015 .
[3] Young T. Hong,et al. Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. , 2015, ACS medicinal chemistry letters.
[4] A. Ströhle,et al. Prescription Patterns of Psychotropic Medications for the Treatment of Psychotic Disorders in the Largest Mental Health Institutions of Uganda , 2014, Journal of clinical psychopharmacology.
[5] A. Hannan,et al. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. , 2014, Human molecular genetics.
[6] X. Shao,et al. Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). , 2014, Nuclear medicine and biology.
[7] M. Mohutsky,et al. Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk , 2014, Drug Metabolism and Disposition.
[8] Gi Fay Mok,et al. Smad1 transcription factor integrates BMP2 and Wnt3a signals in migrating cardiac progenitor cells , 2014, Proceedings of the National Academy of Sciences.
[9] X. Shao,et al. Radiosynthesis of [11C]PyrATP1, a novel radiotracer targeting the ATP-binding site of GSK-3{beta} , 2014 .
[10] Stephen L. Abrams,et al. GSK-3 as potential target for therapeutic intervention in cancer , 2014, Oncotarget.
[11] J. DeFelipe,et al. Selective alterations of neurons and circuits related to early memory loss in Alzheimer’s disease , 2014, Front. Neuroanat..
[12] E. Tolosa,et al. A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.
[13] H. Huppertz,et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial , 2014, Movement disorders : official journal of the Movement Disorder Society.
[14] P. Brauns-Schubert,et al. GSK-3 – at the crossroads of cell death and survival , 2014, Journal of Cell Science.
[15] Wei Chen,et al. Association of glycogen synthase kinase-3β with Parkinson’s disease (Review) , 2014, Molecular medicine reports.
[16] C. Keller,et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma , 2014, Proceedings of the National Academy of Sciences.
[17] M. Donowitz,et al. AKT and GSK-3 Are Necessary for Direct Ezrin Binding to NHE3 as Part of a C-terminal Stimulatory Complex , 2014, The Journal of Biological Chemistry.
[18] A. Sawa,et al. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application , 2014, Translational Psychiatry.
[19] M. Pardo,et al. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. , 2014, Pharmacology & therapeutics.
[20] M. Taha,et al. Naproxen and Cromolyn as New Glycogen Synthase Kinase 3β Inhibitors for Amelioration of Diabetes and Obesity: An Investigation by Docking Simulation and Subsequent In Vitro/In Vivo Biochemical Evaluation , 2013, Journal of biochemical and molecular toxicology.
[21] Weiping Liu,et al. Parkinson's Disease-Associated Dj-1 Mutations Increase Abnormal Phosphorylation of Tau Protein through Akt/Gsk-3β Pathways , 2013, Journal of Molecular Neuroscience.
[22] Hong-Zhuan Chen,et al. Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells , 2013, Acta Pharmacologica Sinica.
[23] Shanshan Ma,et al. GSK‐3α/β‐mediated phosphorylation of CRMP‐2 regulates activity‐dependent dendritic growth , 2013, Journal of neurochemistry.
[24] M. Vázquez-Carrera,et al. Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1-7) action on these pathways in cultured human myotubes. , 2013, Cellular signalling.
[25] K. Cassidy,et al. Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure , 2013, Drug Metabolism and Disposition.
[26] J. DeFelipe,et al. Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3β-overexpressing mice , 2013, Molecular Psychiatry.
[27] C. Pérez,et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. , 2013, ACS chemical neuroscience.
[28] J. DeFelipe,et al. GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo , 2013, Molecular Psychiatry.
[29] M. Wiśniewska. Physiological Role of β-Catenin/TCF Signaling in Neurons of the Adult Brain , 2013, Neurochemical Research.
[30] F. J. Luque,et al. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. , 2013, European journal of medicinal chemistry.
[31] Shou-Jiang Gao,et al. HIV-1 Tat Promotes Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) vIL-6-Induced Angiogenesis and Tumorigenesis by Regulating PI3K/PTEN/AKT/GSK-3β Signaling Pathway , 2013, PloS one.
[32] David J. Fleet,et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.
[33] P. Blower,et al. World Molecular Imaging Congress , 2013 .
[34] Yongbing Chen,et al. [Judging the postoperative lymph node metastasis of esophagus cancer patients with pN0 stage by detecting MTA1 protein expression]. , 2012, Zhonghua yi xue za zhi.
[35] R. Jope,et al. Glycogen synthase kinase‐3 levels and phosphorylation undergo large fluctuations in mouse brain during development , 2012, Bipolar disorders.
[36] M. Svensson,et al. Imidazopyridine‐Based Inhibitors of Glycogen Synthase Kinase 3: Synthesis and Evaluation of Amide Isostere Replacements of the Carboxamide Scaffold , 2012, Chemistry & biodiversity.
[37] Mark Denham,et al. Glycogen Synthase Kinase 3β and Activin/Nodal Inhibition in Human Embryonic Stem Cells Induces a Pre-Neuroepithelial State That Is Required for Specification to a Floor Plate Cell Lineage , 2012, Stem cells.
[38] M. Carducci,et al. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics , 2012, Investigational New Drugs.
[39] C. So,et al. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/&bgr;-catenin pathway , 2012, Current opinion in hematology.
[40] Shih-ku Lin,et al. Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes , 2012, BMC Psychiatry.
[41] Sven Hellberg,et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. , 2012, Journal of medicinal chemistry.
[42] V. Palomo,et al. 5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[43] Alan A. Wilson,et al. Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation. , 2012, Bioorganic & medicinal chemistry letters.
[44] J. Roder,et al. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.
[45] C. Pérez,et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. , 2012, Journal of medicinal chemistry.
[46] J. Beaulieu,et al. Molecular Neuroscience Review Article Gsk-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder , 2022 .
[47] J. Beaulieu,et al. Inhibition of GSK3 by lithium, from single molecules to signaling networks , 2012, Front. Mol. Neurosci..
[48] C. Pérez,et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. , 2011, Journal of medicinal chemistry.
[49] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[50] Ana Martínez,et al. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..
[51] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[52] E. Beurel. Regulation by Glycogen Synthase Kinase-3 of Inflammation and T Cells in CNS Diseases , 2011, Front. Mol. Neurosci..
[53] L. Ivashkiv,et al. Tumor necrosis factor induces GSK3 kinase–mediated cross-tolerance to endotoxin in macrophages , 2011, Nature Immunology.
[54] C. Sutherland. What Are the bona fide GSK3 Substrates? , 2011, International journal of Alzheimer's disease.
[55] F. J. Luque,et al. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. , 2011, Journal of medicinal chemistry.
[56] O. Forlenza,et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial , 2011, British Journal of Psychiatry.
[57] M. Guarnieri,et al. A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. , 2011, Assay and drug development technologies.
[58] Gernot Frenking,et al. Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. , 2011, Journal of the American Chemical Society.
[59] Matthew D. Wessel,et al. 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[60] A. Oro,et al. Cell Migration: GSK3β Steers the Cytoskeleton's Tip , 2011, Cell.
[61] J. Woodgett,et al. Tissue-Specific Analysis of Glycogen Synthase Kinase-3α (GSK-3α) in Glucose Metabolism: Effect of Strain Variation , 2011, PloS one.
[62] G. Hutchins,et al. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3). , 2011, Bioorganic & medicinal chemistry letters.
[63] Humberto González-Díaz,et al. First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines , 2011, Molecular Diversity.
[64] Gangchun Wang,et al. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. , 2010, Bipolar disorders.
[65] Alan A. Wilson,et al. Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECT , 2010, Molecules.
[66] R. Jope,et al. Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes , 2010, Neuroscience.
[67] Eun-Mi Hur,et al. GSK3 signalling in neural development , 2010, Nature Reviews Neuroscience.
[68] I. García,et al. Using Topological Indices to Predict Anti-Alzheimer and Anti-Parasitic GSK-3 Inhibitors by Multi-Target QSAR in Silico Screening , 2010, Molecules.
[69] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[70] F. Gaunitz,et al. 4-Aminoethylamino-emodin – a novel potent inhibitor of GSK-3β– acts as an insulin-sensitizer avoiding downstream effects of activated β-catenin , 2009, Journal of cellular and molecular medicine.
[71] Li-xiang Lin,et al. Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway , 2010, Molecular Biology Reports.
[72] P. S. Klein,et al. Validating GSK3 as an in vivo target of lithium action. , 2009, Biochemical Society transactions.
[73] T. Gómez-Isla,et al. A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo , 2009, Neurobiology of Disease.
[74] H. Möller,et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. , 2009, The Journal of clinical psychiatry.
[75] Ian Collins,et al. Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.
[76] J. Walling,et al. A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas , 2009, Clinical Cancer Research.
[77] S. Hellberg,et al. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. , 2009, The Journal of clinical investigation.
[78] M. Oya,et al. GSK-3 IS A POTENTIAL THERAPEUTIC TARGET FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC): PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION , 2009 .
[79] J. Kunitomo,et al. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. , 2009, Bioorganic & medicinal chemistry.
[80] P. Cohen. Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. , 2009, The Biochemical journal.
[81] B. Doble,et al. Tissue-Specific Role of Glycogen Synthase Kinase 3β in Glucose Homeostasis and Insulin Action , 2008, Molecular and Cellular Biology.
[82] S. Lovestone,et al. A feasibility and tolerability study of lithium in Alzheimer's disease , 2008, International journal of geriatric psychiatry.
[83] M. Portella,et al. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. , 2008, The Journal of clinical psychiatry.
[84] Simon Lovestone,et al. The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.
[85] CRP CHD Genetics Collaboration,et al. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation , 2008, European Journal of Epidemiology.
[86] Yong Eun Kim,et al. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. , 2007, Bioorganic & medicinal chemistry letters.
[87] Ana Martínez,et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. , 2007, Journal of natural products.
[88] M. Ding,et al. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. , 2007, Cancer research.
[89] O. Forlenza,et al. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder , 2007, British Journal of Psychiatry.
[90] B. Doble,et al. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium , 2007, Journal of circadian rhythms.
[91] H. Gendelman,et al. Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. , 2007, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.
[92] R. Jope,et al. Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics , 2007, Neurochemical Research.
[93] H. Gendelman,et al. Glycogen Synthase Kinase 3 Beta (GSK-3β) as a Therapeutic Target in NeuroAIDS , 2007, Journal of Neuroimmune Pharmacology.
[94] A. Xu,et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. , 2006, Cancer research.
[95] N. Kay,et al. Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NFkB Nuclear Activity. , 2006 .
[96] S. Mudaliar,et al. Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. , 2006, American journal of physiology. Endocrinology and metabolism.
[97] B. Tekwani,et al. Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. , 2006, Journal of natural products.
[98] S. A. Thomson,et al. Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3. , 2006, Bioorganic & medicinal chemistry letters.
[99] D. Alonso,et al. Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors , 2006 .
[100] A. Ougolkov,et al. Targeting GSK-3: a promising approach for cancer therapy? , 2006, Future oncology.
[101] H. Wu,et al. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.
[102] H. Wu,et al. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. , 2006, Oncogene.
[103] Alan A. Wilson,et al. Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies. , 2005, Bioorganic & medicinal chemistry letters.
[104] R. Campbell,et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .
[105] R. Cardiff,et al. Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. , 2005, Cancer research.
[106] G. Mills,et al. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. , 2005, Cancer research.
[107] Brian Cunningham,et al. The development of potent and selective bisarylmaleimide GSK3 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[108] G. Agam,et al. Low GSK-3β in schizophrenia as a consequence of neurodevelopmental insult , 2005, European Neuropsychopharmacology.
[109] J. Kuemmerle. Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 beta activity. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[110] P. Greengard,et al. Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.
[111] S. A. Thomson,et al. Novel GSK-3 Inhibitor with Improved Cellular Activity. , 2004 .
[112] S. Wahyuono,et al. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. , 2004, Journal of medicinal chemistry.
[113] R. Campbell,et al. Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. , 2004, Journal of medicinal chemistry.
[114] Michel Goedert,et al. GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.
[115] S. A. Thomson,et al. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[116] S. A. Thomson,et al. Novel GSK-3 inhibitors with improved cellular activity. , 2004, Bioorganic & medicinal chemistry letters.
[117] Kirk W. Johnson,et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.
[118] R. Hill,et al. The manzamine alkaloids. , 2004, The Alkaloids. Chemistry and biology.
[119] R. Jope,et al. Glycogen synthase kinase-3&bgr; is highly activated in nuclei and mitochondria , 2003, Neuroreport.
[120] C. Pérez,et al. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. , 2003, Journal of medicinal chemistry.
[121] Claudia K Derian,et al. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. , 2003, Bioorganic & medicinal chemistry letters.
[122] R. Jope. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. , 2003, Trends in pharmacological sciences.
[123] B. Doble,et al. GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.
[124] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[125] R. Eglen,et al. A High-Throughput, Nonisotopic, Competitive Binding Assay for Kinases Using Nonselective Inhibitor Probes (ED-NSIP™) , 2002, Journal of biomolecular screening.
[126] C. Pérez,et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.
[127] R. Belmaker,et al. GSK-3 and the neurodevelopmental hypothesis of schizophrenia , 2002, European Neuropsychopharmacology.
[128] R. Jope,et al. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.
[129] R. Jope,et al. Proapoptotic Stimuli Induce Nuclear Accumulation of Glycogen Synthase Kinase-3β* , 2001, The Journal of Biological Chemistry.
[130] R. Belmaker,et al. Low GSK-3 activity in frontal cortex of schizophrenic patients , 2001, Schizophrenia Research.
[131] P. Cohen,et al. GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.
[132] James R. Woodgett,et al. Judging a Protein by More Than Its Name: GSK-3 , 2001, Science's STKE.
[133] G. Fava,et al. Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. , 2001, The Journal of clinical psychiatry.
[134] P. Lochhead,et al. Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression , 2001 .
[135] P. Lochhead,et al. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. , 2001, Diabetes.
[136] E. ter Haar,et al. Structure of GSK3beta reveals a primed phosphorylation mechanism. , 2001, Nature structural biology.
[137] J. Woodgett,et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.
[138] R. Belmaker,et al. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. , 2000, The American journal of psychiatry.
[139] Gregory J. Parker,et al. Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays , 2000, Journal of biomolecular screening.
[140] S. Mudaliar,et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. , 2000, Diabetes.
[141] J. Woodgett,et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.
[142] P. Cohen,et al. A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin , 1999, FEBS letters.
[143] R A Roth,et al. The Role of Glycogen Synthase Kinase 3β in Insulin-stimulated Glucose Metabolism* , 1999, The Journal of Biological Chemistry.
[144] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[145] Chris Sander,et al. Objectively judging the quality of a protein structure from a Ramachandran plot , 1997, Comput. Appl. Biosci..
[146] D. Melton,et al. A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[147] K. Imahori,et al. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[148] J. Woodgett,et al. Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.
[149] Philip R. Cohen,et al. Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). , 1984, Biochimica et biophysica acta.
[150] P. Cohen,et al. Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.
[151] P. Cohen,et al. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.